The co-developer of the vaccine Astrazeneca assures that there is "very reassuring evidence" of the safety of the product.
For some time, this vaccine appears to be controversial.
It was suspended, for prevention, in several European countries after possible blood clot formation in the vaccinated.
The vaccine against Covid-19 developed by the Swedish-British pharmaceutical group AstraZeneca with the University of Oxford is safe, assured its co-developer after concerns that led to the suspension of its use in several countries.
There is "very reassuring evidence that there is no increase in the blood clot phenomenon here in the UK, where most of the doses in Europe have been administered so far," said Monday to the BBC Professor Andrew Pollard, director of the Oxford Vaccine Group which developed the vaccine with AstraZeneca.
He stressed the importance of continuing the vaccination against the coronavirus, a disease which presents a "huge risk" to health.
Reassuring figures
In a statement on Sunday, AstraZeneca said that "a careful review of all available safety data on more than 17 million people vaccinated in the European Union and the UK" with its vaccine "has yielded no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia in any particular age group, gender, lot or country ”.
>>
LIVE
- Coronavirus: follow the evolution of the situation Monday March 15
"About 17 million people in the European Union and the United Kingdom have now received our vaccine, and the number of blood clot cases reported in this group is lower than the hundreds of cases one would expect in the general population. ", compared Dr. Ann Taylor, chief medical officer, in this release.
AstraZeneca injections suspended in several European countries
The Dutch government decided on Sunday to suspend the use of this vaccine as a precaution, until March 28 inclusive, after "possible side effects" were reported in Denmark and Norway with the AstraZeneca vaccine, with no proven link to this. stage, according to the Ministry of Health.
Earlier today, Ireland had taken the same decision after reports in Norway of four new serious cases of blood clots in vaccinated adults.
Norway, which also reported skin hemorrhages in vaccinated young people on Saturday, suspended the vaccine last week, as did Denmark, Iceland and Bulgaria.